ES2135051T3 - Peptidos derivados de mage-3, aislados, que forman complejos con moleculas hla-a2 y usos de los mismos. - Google Patents

Peptidos derivados de mage-3, aislados, que forman complejos con moleculas hla-a2 y usos de los mismos.

Info

Publication number
ES2135051T3
ES2135051T3 ES95914752T ES95914752T ES2135051T3 ES 2135051 T3 ES2135051 T3 ES 2135051T3 ES 95914752 T ES95914752 T ES 95914752T ES 95914752 T ES95914752 T ES 95914752T ES 2135051 T3 ES2135051 T3 ES 2135051T3
Authority
ES
Spain
Prior art keywords
mage
hla
molecules
isolated
peptides derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914752T
Other languages
English (en)
Inventor
Der Bruggen Pierre Van
Thierry Boon-Falleur
Catia Traversari
Katharina Fleischauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2135051T3 publication Critical patent/ES2135051T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE HAN IDENTIFICADO LOS ANTIGENOS DE RECHAZO DE TUMORES DERIVADOS DE PRECURSOR DE RECHAZO MAGE-3. DICHOS ANTIGENOS, SE UNEN A LA MOLECULA DE HLA-A2, CLASE I DEL CMH, Y LOS COMPLEJOS RESULTANTES ESTIMULAN LA PRODUCCION DE CLONES DE CELULAS T CITOLITICAS, QUE LISAN LAS CELULAS PRESENTADORAS. DICHOS PEPTIDOS Y COMPLEJOS, PUEDEN SER UTILIZADOS EN EL DIAGNOSTICO, TERAPEUTICA, Y COMO INMUNOGENOS PARA LA PRODUCCION DE ANTICUERPOS, O COMO DIANAS PARA LA GENERACION DE CLONES DE CELULAS T CITOLITICAS.
ES95914752T 1994-03-24 1995-03-21 Peptidos derivados de mage-3, aislados, que forman complejos con moleculas hla-a2 y usos de los mismos. Expired - Lifetime ES2135051T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/217,187 US5554506A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Publications (1)

Publication Number Publication Date
ES2135051T3 true ES2135051T3 (es) 1999-10-16

Family

ID=22810011

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914752T Expired - Lifetime ES2135051T3 (es) 1994-03-24 1995-03-21 Peptidos derivados de mage-3, aislados, que forman complejos con moleculas hla-a2 y usos de los mismos.

Country Status (16)

Country Link
US (3) US5554506A (es)
EP (1) EP0759032B1 (es)
JP (1) JP3451356B2 (es)
CN (1) CN1142177C (es)
AT (1) ATE183195T1 (es)
AU (1) AU682956B2 (es)
CA (1) CA2186005A1 (es)
DE (1) DE69511399T2 (es)
DK (1) DK0759032T3 (es)
ES (1) ES2135051T3 (es)
FI (1) FI963781A0 (es)
GR (1) GR3031811T3 (es)
NZ (1) NZ283543A (es)
TW (1) TW496875B (es)
WO (1) WO1995025739A1 (es)
ZA (1) ZA952376B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5827073A (en) * 1995-07-05 1998-10-27 Ludwig Institute For Cancer Research Photoreactive peptide derivatives
US6087441A (en) 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
WO1998058951A1 (en) 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
JP4540033B2 (ja) 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および／または増強する方法
AU2001229681A1 (en) * 2000-01-20 2001-07-31 Ludwig Institute For Cancer Research Mage antigenic peptides which bind hla-b35 and hla-b44
ATE513913T1 (de) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
DE60238864D1 (de) * 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
US20070105779A1 (en) * 2002-07-31 2007-05-10 Danila Valmori Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
WO2007018199A1 (ja) * 2005-08-09 2007-02-15 Kumamoto University HLA-A2陽性者用glypican-3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Also Published As

Publication number Publication date
FI963781A (fi) 1996-09-23
ZA952376B (en) 1995-12-14
NZ283543A (en) 1998-04-27
GR3031811T3 (en) 2000-02-29
JP3451356B2 (ja) 2003-09-29
CN1151167A (zh) 1997-06-04
AU2187095A (en) 1995-10-09
AU682956B2 (en) 1997-10-23
CA2186005A1 (en) 1995-09-28
ATE183195T1 (de) 1999-08-15
US6353089B1 (en) 2002-03-05
DK0759032T3 (da) 1999-12-27
US5554506A (en) 1996-09-10
EP0759032B1 (en) 1999-08-11
DE69511399T2 (de) 2000-05-11
WO1995025739A1 (en) 1995-09-28
DE69511399D1 (de) 1999-09-16
EP0759032A1 (en) 1997-02-26
CN1142177C (zh) 2004-03-17
TW496875B (en) 2002-08-01
US6019987A (en) 2000-02-01
FI963781A0 (fi) 1996-09-23
JPH10500667A (ja) 1998-01-20
EP0759032A4 (en) 1997-04-09

Similar Documents

Publication Publication Date Title
ES2135051T3 (es) Peptidos derivados de mage-3, aislados, que forman complejos con moleculas hla-a2 y usos de los mismos.
NO963918D0 (no) Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav
ES2061632T3 (es) Kluyveromyces como celula hospedante.
CH520156A (de) Verfahren zur Herstellung neuer Perhydro-5-phenylcyclo-alkapolyen-1,4-oxazepine
AT304870B (de) Verfahren zur Herstellung neuer, harzartiger insbesondere für eine Peptidsynthese geeigneter Verbindungen
NL179286B (nl) Werkwijze voor de bereiding van een geneesmiddel met ontstekingsremmende werking, gevormd geneesmiddel en werkwijze ter bereiding van geneeskrachtige verbindingen, geschikt voor gebruik bij deze werkwijze.
CH498793A (de) Verfahren zur Herstellung von 2,6-Dimethylphenol
AT283536B (de) Verfahren zur Herstellung neuer, sulfonsäuregruppenfreier Monoazofarbstoffe
ES2168514T3 (es) Antigenos de rechazo tumoral presentados por moleculas de hla b44 y usos de los mismos.
CH478866A (de) Verfahren zur Herstellung von hitzebeständigen, linearen, thermoplastischen aromatischen Polythioäthern
BR102017001293A2 (pt) peptídeos sintéticos, método e kit para diagnóstico da leucose bovina, e uso
AT285761B (de) Verfahren zur Herstellung neuer, sulfonsäuregruppenfreier N-Phenyl-phthalimid-monoazofarbstoffe
USD152026S (en) Design fob a cosmetic container
USD133254S (en) Design fob a dress
CH540242A (de) Verfahren zur Herstellung neuer 7a,18-Dialkylöstrene
USD171922S (en) Christmas flag
CH348707A (de) Verfahren zur Herstellung von neuen in 2-Stellung acetylierten 3,5-Diketo-pyrazolidinen
AT267710B (de) Verfahren zur Herstellung neuer, wasserunlöslicher Monoazofarbstoffe
BR102017001300A2 (pt) peptídeos sintéticos, método e kit para diagnóstico da rinotraqueíte infeciosa bovina, e uso
CH555330A (de) Verfahren zur herstellung pharmazeutisch wertvoller 1,4benzodioxane.
AT284859B (de) Verfahren zur Herstellung von neuen hochmolekularen Polybenz-1,3-oxazin-2,4-dionen
CH74570A (de) Verfahren zur Überführung von Tuberkelbazillenpräparaten in dauern haltbare, zur Herstellung von gebrauchsfertigen Injektionsflüssigkeiten geeignete Trockenpräparate
ES137398A1 (es) Procedimiento para la fabricación de artículos en varios colores, mediante la reacción química de resinas sintéticas artificiales y también prensando o moldeando mezclas de resinas sintéticas artificiales.
CH467448A (de) Vorrichtung zur Herstellung von Einbettungspräparaten, insbesondere für mikroskopische und elektronenmikroskopische Zwecke
CH528493A (de) Verfahren zur Herstellung neuer 16a, 17-Alkylidendioxy-18-methyl-9-norprogesterone

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759032

Country of ref document: ES